People who have never used the word “appendix” in a medical sentence now know someone with appendix cancer. Young adults are showing up with colorectal tumors that used to belong to their grandparents. Physicians who spent careers calling certain malignancies “rare” are saying the word less often, and with less confidence.
That observation does not require a conspiracy board. The registries already show it. Appendix cancer in the United States rose 232% between 2000 and 2016. Americans born in the early 1980s are several times more likely to receive that diagnosis than Americans born in the 1940s. Colorectal cancer in people ages 20 to 49 is climbing about 3% a year while it falls in the elderly. Carcinoma rates in adolescents and young adults have been drifting upward for decades. In 2026 the National Cancer Institute still reports that overall cancer deaths are falling. Incidence is another story, especially in the young, and especially in tumors that used to be footnotes.
What the observation does not do is hand the public a finished cause. Obesity, ultra-processed food, childhood antibiotics, lockdowns that postponed screening, better detection, and the virus itself are all in the pile. So are the products that a handful of corporations, armed with federal liability shields and captured regulators, rolled out to the entire population in 2021 and then boosted, and boosted again.
The companies prefer that sentence to end before their names appear. A free country is not required to oblige them.


















You must be logged in to post a comment.